As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Local lawmakers, teachers and parents are speaking out against President Donald Trump’s attempts to dismantle the U.S.

Democratic Gov. Andy Beshear has vetoed legislation that would overrule his executive order limiting conversion therapy on ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

University of Arizona's medical research building in Phoenix is being paused due to "potential changes to federal funding." ...

Disability advocates in New Jersey worry about losing the main funder of special education programs and a chief enforcer of ...

The USDA announced a $100 million investment to facilitate research into therapies and vaccines for bird flu. The funding will be available to vaccine makers, states, and universities. This initiative ...

Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and BioMarin Pharmaceutical. Currently, the analyst consensus on United Therapeutics ...

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, ...

These could include reminiscence therapy, spending time outside, and singing. Some people with dementia may find one of these therapies helpful and there is some research that suggests they can be ...

CAR T-cell therapies have shown unprecedented efficacy in several autoimmune diseases, so far yielding several years of drug-free remission in lupus, rheumatoid arthritis and other conditions.